[Globe Newswire] CempraInc (NASDAQ:CEMP) (TREND ANALYSIS) announced it will be participating in the Wedbush PacGrow 2015 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 4:15 p.m. EDT (1:15 p.m. PDT) on Tuesday, August 11, 2015 in New York.
A live audio webcast and archive of the presentation will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
CempraInc (NASDAQ:CEMP) stock is currently trading 19.75% below its 52-week-high, 309.89% above its 52-week-low. The 1-year stock price history is in the range of $9.2 – $46.99. CempraInc (CEMP) has a price to book ratio of 10.42. CEMP stock price has outperformed the Nasdaq by 53.3%. The Medical Drugs company is currently valued at $1.65 billion and its share price closed the last trading session at $37.71. The stock has a 50-day moving average of $39.42 and a 200-day moving average of $35.17.
CempraInc (CEMP) current short interest stands at 3.32 million shares. It has increased by 16% from the same period of last month. Around 10% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.78 million shares, the number of days required to cover the short positions stand at 4.3 days.
CEMP reported last quarter earnings on July 29. The Medical Drugs company announced earnings per share of $-0.57 against a consensus Street estimate of $-0.41, missing estimate by $0.16. This corresponds to an increase of $0.07 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently nine analysts that cover CempraInc stock. Of those nine, nine have a Buy rating. On a consensus basis this yields to a Buy rating. The consensus target price stands at $52.5.
A recent analyst activity consisted of Morgan Stanley who initiated their coverage on the stock with Equal-weight rating on August 13. Morgan Stanley fixed their price target at $40. This corresponds to a 6.07% upside from the last closing price. On the date of report, the stock closed at $37.71.
Stifel Nicolaus reiterated their Buy stance on June 23, and increased their price target on CEMP stock from $44 to $57. This corresponds to a 51.15% upside from the last closing price. On the date of report, the stock closed at $38.52.
Another research firm was Roth Capital who resumed their coverage on the stock with Buy rating on May 21. Roth Capital decreased price target from $42 to $42. This translates to a 11.38% upside from the last closing price. On the date of report, the stock closed at $36.65.
Cempra, Inc. is a clinical-stage pharmaceutical company. The Company develops antibiotics for the treatment of infectious diseases such as respiratory tract infections, and skin and skin structure infections.